Blog
Champion Homes Q4 Earnings Call Highlights
Key Points
- Interested in Champion Homes, Inc.? Here are five stocks we like better.
- Champion Homes beat a softer housing market in fiscal Q4, with net sales up 4.6% to $621.3 million and
Senstar Technologies Q1 Earnings Call Highlights
Key Points
- Interested in Senstar Technologies Ltd.? Here are five stocks we like better.
- Senstar posted a Q1 loss as revenue fell to $8.1 million from $8.4 million a year earlier, with
Pony AI Q1 Earnings Call Highlights
Key Points
- Interested in Pony AI Inc. - Sponsored ADR? Here are five stocks we like better.
- Q1 revenue surged 145% year over year to $34.3 million, led by a nearly 400% jump in robotaxi
Elbit Systems Q1 Earnings Call Highlights
Key Points
- Interested in Elbit Systems Ltd.? Here are five stocks we like better.
- Elbit Systems posted a strong Q1 2026, with revenue up 15.5% to $2.189 billion, GAAP diluted EPS up 42% to
Ituran Location and Control Q1 Earnings Call Highlights
Key Points
- Interested in Ituran Location and Control Ltd.? Here are five stocks we like better.
- Ituran posted a record Q1 2026 with revenue of $102.7 million, up 19% year over year, as
Freightos Q1 Earnings Call Highlights
Key Points
- Interested in Freightos Limited? Here are five stocks we like better.
- Freightos had a softer-than-expected Q1 as Middle East trade disruptions reduced transaction growth, with
5 Stocks Winning the AI Race While Everyone Watches NVIDIA
Key Points
- Interested in Micron Technology, Inc.? Here are five stocks we like better.
- Keith Kaplan of TradeSmith identifies five physical "choke points" in the AI build-out—high bandwidth
Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data
Key Points
- Interested in Kymera Therapeutics, Inc.? Here are five stocks we like better.
- Kymera said its lead program KT-621 remains on schedule in Phase IIb trials for atopic dermatitis and
Yatsen Q1 Earnings Call Highlights
Key Points
- Interested in Yatsen Holding Limited Sponsored ADR? Here are five stocks we like better.
- Revenue grew 22.5% year over year to CNY 1.02 billion in Q1 2026, driven mainly by a 58.5%
Berkshire Sells Visa, Domino's, and Pool Corp: Should You Follow?
Key Points
- Interested in Visa Inc.? Here are five stocks we like better.
- Berkshire Hathaway's first 13F under CEO Greg Abel shows the company exited 16 positions totaling $8.1 billion, its
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts
Key Points
- Interested in Karyopharm Therapeutics Inc.? Here are five stocks we like better.
- Karyopharm highlighted upcoming milestones for selinexor, including an ASCO late-breaking
Alphabet Just Unveiled Its Most Ambitious AI Lineup Yet
Key Points
- Interested in Alphabet Inc.? Here are five stocks we like better.
- At Google I/O 2026, Alphabet unveiled a suite of new AI models and features, including Gemini 3.5 Flash, Omni, and
Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus
Key Points
- Interested in Karyopharm Therapeutics Inc.? Here are five stocks we like better.
- Karyopharm said it will present fuller Phase 3 SENTRY data for selinexor in newly diagnosed
Atalaya Mining Q1 Earnings Call Highlights
Key Points
- Interested in Atalaya Mining Plc? Here are five stocks we like better.
- Q1 production was hit by heavy rain in Spain, but Atalaya still generated €14 million of EBITDA and nearly €30
KLA Flags Stronger Chip Equipment Demand, Rare 2027 Visibility at JPMorgan Conference
Key Points
- Interested in KLA Corporation? Here are five stocks we like better.
- KLA said semiconductor equipment demand is strengthening across leading-edge logic, memory and advanced
J.B. Hunt Highlights Intermodal Share Gains, Pricing Upside at Wolfe Conference
Key Points
- Interested in J.B. Hunt Transport Services, Inc.? Here are five stocks we like better.
- Intermodal demand is steady, but J.B. Hunt said recent volume gains are being driven more by
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges
Key Points
- Interested in Disc Medicine, Inc.? Here are five stocks we like better.
- Disc Medicine said enrollment in its APOLLO confirmatory study for bitopertin in EPP reached 183 patients
JOYY Q1 Earnings Call Highlights
Key Points
- Interested in JOYY Inc.? Here are five stocks we like better.
- JOYY posted strong Q1 2026 results, with total net revenue up 12.4% year over year to $555.7 million and non-GAAP
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst
Key Points
- Interested in Opus Genetics, Inc.? Here are five stocks we like better.
- Opus Genetics highlighted a broad inherited retinal disease gene therapy pipeline, with two programs already
PPDAI Group Q1 Earnings Call Highlights
Key Points
- Interested in PPDAI Group Inc. Sponsored ADR? Here are five stocks we like better.
- FinVolution posted a steady first quarter of 2026, with net revenue up 6% sequentially to RMB 3.2
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
Key Points
- Interested in Ionis Pharmaceuticals, Inc.? Here are five stocks we like better.
- Ionis has a packed 2026-style catalyst calendar with two PDUFA dates for wholly owned drugs —
Intel CEO Touts Balance Sheet Progress, Foundry Gains and AI CPU Demand
Key Points
- Interested in Intel Corporation? Here are five stocks we like better.
- CEO Lip-Bu Tan said Intel has made early progress on strengthening its balance sheet, improving execution, and
Intapp Says AI Is Driving Demand as Celeste Tackles Compliance Risks
Key Points
- Interested in Intapp, Inc.? Here are five stocks we like better.
- AI is becoming a growth driver for Intapp as professional-services firms look for ways to automate work without
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
Key Points
- Interested in Inovio Pharmaceuticals, Inc.? Here are five stocks we like better.
- Shareholders approved all proposals at Inovio’s 2026 annual meeting, including the election of eight
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out
Key Points
- Interested in Incyte Corporation? Here are five stocks we like better.
- Incyte plans to start a Phase 3 trial of mutant CALR antibody 989 in essential thrombocythemia around